<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOTREL - amlodipine besylate and benazepril hydrochloride capsule </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use</span><span class="Bold"> Lotrel</span> <span class="Bold">safely and effectively.</span><span class="Bold"> </span><span class="Bold">See full prescribing information for Lotrel.</span><br><span class="Bold">Lotrel (amlodipine besylate and benazepril hydrochloride) Capsules</span><br><span class="Bold">Initial U.S. Approval:</span><span class="Bold"> </span><span class="Bold">1995</span><br>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: FETAL TOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold">When pregnancy is detected, discontinue Lotrel as soon as possible (<a href="#s5p4">5.4</a>).  Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus (<a href="#s5p4">5.4</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Boxed Warning: Fetal Toxicity   
		     
	01/2012 </p>
<p class="Highlighta">Warnings and Precautions: Fetal Toxicity (<a href="#s5p4">5.4</a>)  
		     
	01/2012 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: FETAL TOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold">When pregnancy is detected, discontinue Lotrel as soon as possible (<a href="#s5p4">5.4</a>).  Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus (<a href="#s5p4">5.4</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Lotrel is a combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Lotrel is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in patients not adequately controlled on monotherapy with either agent (<a href="#s1">1</a>) </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Dose once-daily<br>
</li>
<li>May be used as add-on therapy for patients not adequately controlled with either a dihydropyridine calcium channel blocker or an ACE inhibitor (<a href="#s2p2">2.2</a>)<br>
</li>
<li>Patients who experience <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> with amlodipine may be switched to Lotrel containing a lower dose of amlodipine (<a href="#s2p2">2.2</a>) <br>
</li>
<li>Start Lotrel at 2.5/10 mg in patients ≥ 75 years old or in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#s2">2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules (amlodipine/benazepril mg):  2.5/10, 5/10, 5/20, 5/40, 10/20, 10/40 (<a href="#s3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Lotrel is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, with or without previous ACE inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ACE inhibitor, or to amlodipine.  (<a href="#s4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Watch for <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (head, neck or intestinal). <br>
</li>
<li> Warn patients with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> about the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or increased angina (<a href="#s5p2">5.2</a>)<br>
</li>
<li>Assess for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>  (<a href="#s5p3">5.3</a> and <a href="#s5p7">5.7</a>)<br>
</li>
<li>Titrate slowly in patients with impaired hepatic (<a href="#s5p5">5.5</a>) or severely impaired renal (<a href="#s5p6">5.6</a>) function. <br>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Discontinuation because of adverse reactions occurred in 4% of Lotrel-treated patients and 3% of placebo-treated patients.  The most common reasons for discontinuation of therapy with Lotrel were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. (<a href="#s6">6</a>) </p>
<span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Potassium supplements / Potassium-sparing diuretics:  risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span><br>
</li>
<li>Lithium:  Increased serum Lithium levels;  toxicity symptoms<br>
</li>
<li>Injectable gold:  <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur</li>
<li>NSAID: Risk of renal dysfunction, loss of antihypertensive effect (<a href="#s7p1">7.1</a>)</li>
<li>If simvastatin is co-administered with amlodipine, do not exceed doses greater than 20 mg daily of simvastatin (<a href="#s7p1">7.1</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta"><span class="Bold">Nursing Mothers:</span> It is not known whether amlodipine is excreted in human milk.  Nursing or drug should be discontinued.  (<a href="#s8p3">8.3</a>)<br><br> </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION, and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 3/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: FETAL TOXICITY</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1</span><span class="Bold">  </span><span class="Bold">INDICATIONS AND USAGE</span></a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1</span><span class="Bold"> </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span><span class="Bold">  </span><span class="Bold">DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.2 Add-on Therapy</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.3 Replacement Therapy</span><span class="Bold"> </span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3  </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span><span class="Bold"> </span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4</span><span class="Bold">  </span><span class="Bold">CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5</span><span class="Bold">  </span><span class="Bold">WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 </span><span class="Bold">Anaphylact</span><span class="Bold">o</span><span class="Bold">i</span><span class="Bold">d and Possibly Related Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 </span><span class="Bold">Increased Angina and/or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.</span><span class="Bold">3 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 Fetal Toxicity</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></span><span class="Bold"> </span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.</span><span class="Bold">8 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.</span><span class="Bold">9 </span><span class="Bold">Surgery/Ane</span><span class="Bold">s</span><span class="Bold">thesia</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6</span><span class="Bold">  </span><span class="Bold">ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 </span><span class="Bold">Clinical </span><span class="Bold">Trials </span><span class="Bold">Experience</span><span class="Bold"> </span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 Post-marketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7</span><span class="Bold">  </span><span class="Bold">DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 </span><span class="Bold">Drug/Drug interactions</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.2 Clinical Laboratory Test Findings</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8</span><span class="Bold">  </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 </span><span class="Bold">Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.2 </span><span class="Bold">Labor and Delivery</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.3 </span><span class="Bold">Nursing Mothers</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.4 </span><span class="Bold">Pediatric Use</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.5 </span><span class="Bold">Geriatric Use</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10</span><span class="Bold">  </span><span class="Bold">OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11  DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12</span><span class="Bold">  </span><span class="Bold">CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 </span><span class="Bold">Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2 </span><span class="Bold">Pharmacodynamics</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3 </span><span class="Bold">Pharmacokinetics</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13  </span><span class="Bold">NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">13.3 </span><span class="Bold">Reproductive </span><span class="Bold">Toxicity</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14  </span><span class="Bold">CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16</span><span class="Bold">  </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17</span><span class="Bold">  </span><span class="Bold">PATIENT COUNSELING INFORMATION</span></a></h1>
<h2><a href="#section-15.1" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: FETAL TOXICITY</span></h1>
<p class="First"><span class="Bold">When pregnancy is detected, discontinue Lotrel as soon as possible (5.4).  Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus (5.4)</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>
<span class="Bold">1</span><span class="Bold">  </span><span class="Bold">INDICATIONS AND USAGE</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s1p1"></a><a name="section-1.1"></a><p></p>
<h2>
<span class="Bold">1.1</span><span class="Bold"> </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span>
</h2>
<p class="First">Lotrel is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in patients not adequately controlled on monotherapy with either agent.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span><span class="Bold">  </span><span class="Bold">DOSAGE AND ADMINISTRATION</span>
</h1>
<p class="First">Amlodipine is an effective treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in once-daily doses of 2.5-10 mg while benazepril is effective in doses of 10-80 mg. In clinical trials of amlodipine/benazepril combination therapy using amlodipine doses of 2.5-10 mg and benazepril doses of 10-40 mg, the antihypertensive effects increased with increasing dose of amlodipine in all patient groups, and the effects increased with increasing dose of benazepril in nonblack groups. </p>
<p>The antihypertensive effect of Lotrel is largely attained within 2 weeks. </p>
<p>It is usually appropriate to begin therapy with Lotrel only after a patient has either (a) failed to achieve the desired antihypertensive effect with one or the other monotherapy, or (b) demonstrated inability to achieve adequate antihypertensive effect with amlodipine therapy without developing <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span>  Regimens of therapy with Lotrel need not take account of renal function as long as the patient’s creatinine clearance is &gt;30 mL/min/1.73m<span class="Sup">2</span> (serum creatinine roughly ≤3 mg/dL or 265 µmol/L). Lotrel is not recommended in patients with more severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><span class="Bold"> and Elderly Patients</span><span class="Bold">:</span>  The recommended initial dose of amlodipine, as monotherapy or as a component of combination therapy, is 2.5 mg. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p2"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.2 Add-on Therapy</span></h2>
<p class="First">A patient whose blood pressure is not adequately controlled with amlodipine (or another dihydropyridine) alone or with benazepril (or another ACE inhibitor) alone may be switched to combination therapy with Lotrel. </p>
<p>In patients whose blood pressure is adequately controlled with amlodipine but who experience unacceptable <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, combination therapy may achieve similar (or better) blood pressure control with less <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p3"></a><a name="section-2.2"></a><p></p>
<h2>
<span class="Bold">2.3 Replacement Therapy</span><span class="Bold"> </span>
</h2>
<p class="First">Lotrel may be substituted for the titrated components.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>
<span class="Bold">3  </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span><span class="Bold"> </span>
</h1>
<p class="First">Lotrel (amlodipine/benazepril) capsules are available as follows:</p>
<p>2.5/10 mg, 5/10 mg, 5/20 mg, 5/40 mg, 10/20 mg, and 10/40 mg.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>
<span class="Bold">4</span><span class="Bold">  </span><span class="Bold">CONTRAINDICATIONS</span>
</h1>
<p class="First">Lotrel is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, with or without previous ACE inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ACE inhibitor, or to amlodipine.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>
<span class="Bold">5</span><span class="Bold">  </span><span class="Bold">WARNINGS AND PRECAUTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p1"></a><a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1 </span><span class="Bold">Anaphylact</span><span class="Bold">o</span><span class="Bold">i</span><span class="Bold">d and Possibly Related Reactions</span>
</h2>
<p class="First">Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including Lotrel) may be subject to a variety of adverse reactions, some of them serious. These reactions usually occur after one of the first few doses of the ACE inhibitor, but they sometimes do not appear until after months of therapy. Black patients receiving ACE inhibitors have a higher incidence of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> compared to nonblacks.</p>
<p><span class="Bold Italics">Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, extremities, lips, tongue, glottis, and larynx has been reported in patients treated with ACE inhibitors. In U.S. clinical trials, symptoms consistent with <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> were seen in none of the subjects who received placebo and in about 0.5% of the subjects who received benazepril. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> can be fatal. If laryngeal <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> of the face, tongue, or glottis occurs, discontinue treatment with Lotrel  and treat  immediately. <span class="Italics">When involvement of the tongue, glottis, or larynx appears likely to cause airway obstruction, appropriate therapy, e.g., </span><span class="Italics">administer </span><span class="Italics">subcutaneous epinephrine injection 1:1000 (0.3-0.5 mL),</span><span class="Italics"> promptly</span> [see<span class="Italics"> Adverse Reactions (6)</span>].</p>
<p><span class="Bold Italics">Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</span> Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> has been reported in patients treated with ACE inhibitors. These patients presented with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (with or without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>); in some cases there was no prior history of facial <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and C-1 esterase levels were normal. The <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> should be included in the differential diagnosis of patients on ACE inhibitors presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> During Desensitization:</span> Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> During Membrane Exposure:</span> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p2"></a><a name="section-5.2"></a><p></p>
<h2>
<span class="Bold">5.2 </span><span class="Bold">Increased Angina and/or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span>
</h2>
<p class="First">Rarely, patients, particularly those with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, have developed documented increased frequency, duration or severity of angina or <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> on starting calcium channel blocker therapy or at the time of dosage increase. The mechanism of this effect has not been elucidated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p3"></a><a name="section-5.3"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">3 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span>
</h2>
<p class="First">Lotrel can cause symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is most likely to occur in patients who have been volume or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, with or without associated <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, ACE inhibitor therapy may cause excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, which may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. In such patients, start Lotrel therapy  under close medical supervision;  follow closely for the first 2 weeks of treatment and whenever the dose of the benazepril component is increased or a diuretic is added or its dose increased.</p>
<p>Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is also possible in patients with severe <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>.</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, place the patient in a supine position, and if necessary, treat with intravenous infusion of physiologic saline. Lotrel treatment usually can be continued following restoration of blood pressure and volume.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p4"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 Fetal Toxicity</span></h2>
<p class="First"><span class="Bold">Pregnancy Category D</span></p>
<p><span class="Xmchange"></span>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations.  Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  When pregnancy is detected, discontinue Lotrel as soon as possible  [<span class="Italics">see Use in Specific Populations (8.1)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p5"></a><a name="section-5.5"></a><p></p>
<h2>
<span class="Bold">5.5 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></span><span class="Bold"> </span>
</h2>
<p class="First">Rarely, ACE inhibitors have been associated with a syndrome that starts with <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and progresses to fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and, sometimes, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p>
<p>In patients with hepatic dysfunction due to cirrhosis, levels of benazeprilat are essentially unaltered.</p>
<p>However, since amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t<span class="Sub">1/2</span>) is 56 hours in patients with impaired hepatic function, titrate Lotrel slowly in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p6"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold">5.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></h2>
<p class="First">Lotrel should not be used in patients with severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>  (Clearance creatinine &lt; 30 ml/min) [see <span class="Italics">Dosage and Administration (2)</span>]. </p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, whose renal function may depend on the activity of the renin-angiotensin aldosterone system, treatment with benazepril may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>In a small study of hypertensive patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, treatment with benazepril was associated with increases in blood urea nitrogen and serum creatinine; these increases were reversible upon discontinuation of benazepril therapy, concomitant diuretic therapy, or both. When such patients are treated with Lotrel, monitor renal function  during the first few weeks of therapy.</p>
<p>Some benazepril-treated hypertensive patients with no apparent preexisting renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient, especially when benazepril has been given concomitantly with a diuretic. Dosage reduction of Lotrel may be required. </p>
<p>Renal function should be monitored periodically in patients receiving benazepril.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p7"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold">5.7 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></h2>
<p class="First">In U.S. placebo-controlled trials of Lotrel, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium at least 0.5 mEq/L greater than the upper limit of normal) not present at baseline occurred in approximately 1.5% of hypertensive patients receiving Lotrel. Increases in serum potassium were generally reversible. Risk factors for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. Serum potassium should be monitored periodically in patients receiving benazepril. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p8"></a><a name="section-5.8"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">8 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span>
</h2>
<p class="First">Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> has been reported with all ACE inhibitors, generally resolving after discontinuation of therapy. Consider ACE inhibitor-induced <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>  in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p9"></a><a name="section-5.9"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">9 </span><span class="Bold">Surgery/Ane</span><span class="Bold">s</span><span class="Bold">thesia</span>
</h2>
<p class="First">In patients undergoing surgery or during anesthesia with agents that produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, benazepril will block the angiotensin II formation that could otherwise occur secondary to compensatory renin release. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> that occurs as a result of this mechanism can be corrected by volume expansion.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>
<span class="Bold">6</span><span class="Bold">  </span><span class="Bold">ADVERSE REACTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>
<span class="Bold">6.1 </span><span class="Bold">Clinical </span><span class="Bold">Trials </span><span class="Bold">Experience</span><span class="Bold"> </span>
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.  The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates. </p>
<p>Lotrel has been evaluated for safety in over 2,991 patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; over 500 of these patients were treated for at least 6 months, and over 400 were treated for more than 1 year.</p>
<p>In a pooled analysis of 5 placebo-controlled trials involving Lotrel doses up to 5/20, the reported side effects were generally mild and transient, and there was no relationship between side effects and age, sex, race, or duration of therapy. Discontinuation of therapy due to side effects was required in approximately 4% of patients treated with Lotrel and in 3% of patients treated with placebo.</p>
<p>The most common reasons for discontinuation of therapy with Lotrel in these studies were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>). </p>
<p>The <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> associated with amlodipine use is dose-dependent.  When benazepril is added to a regimen of amlodipine, the incidence of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> is substantially reduced.  </p>
<p>The addition of benazepril to a regimen of amlodipine should not be expected to provide additional antihypertensive effect in African-Americans. However, all patient groups benefit from the reduction in amlodipine-induced <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>The side effects considered possibly or probably related to study drug that occurred in these trials in more than 1% of patients treated with Lotrel are shown in the table below.  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> was the only adverse event with at least possible relationship to treatment that was more common on Lotrel (3.3%) than on placebo (0.2%).</p>
<a name="i0ff21cd7-85f4-4870-8b18-0508c37985d2"></a><table>
<caption><span>PERCENT INCIDENCE IN U.S. PLACEBO-CONTROLLED TRIALS</span></caption>
<col width="124">
<col width="152">
<col width="124">
<col width="124">
<col width="124">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" valign="bottom"></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">Benazepril/Amlodipine</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">Benazepril</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">Amlodipine</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">Placebo</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" valign="bottom"></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"><span class="Underline">N=760</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"><span class="Underline">N=554</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"><span class="Underline">N=475</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"><span class="Underline">N=408</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" valign="bottom"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">3.3</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">1.8</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">0.4</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">0.2</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" valign="bottom"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">2.2</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">3.8</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">2.9</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">5.6</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" valign="bottom"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">1.3</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">1.6</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">2.3</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">1.5</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" valign="bottom"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>*</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">2.1</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">0.9</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">5.1</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">2.2</td>
</tr>
</tbody>
</table>
<p>*<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> refers to all <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, such as <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">dependent edema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was greater in patients treated with amlodipine monotherapy (5.1%) than in patients treated with Lotrel (2.1%) or placebo (2.2%).</p>
<p>Other side effects considered possibly or probably related to study drug that occurred in U.S. placebo-controlled trials of patients treated with Lotrel or in postmarketing experience were the following:</p>
<p><span class="Bold Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.</p>
<p><span class="Bold Italics">CNS:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and decreased libido.</p>
<p><span class="Bold Italics">Dermatologic:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4042856" conceptname="Fibrous nodule">skin nodule</span>, and <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>.</p>
<p><span class="Bold Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
<p><span class="Bold Italics">Hematologic: </span> <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p>
<p><span class="Bold Italics">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>.</p>
<p><span class="Bold Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>.</p>
<p><span class="Bold Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>.</p>
<p><span class="Bold Italics">Urogenital:</span> Sexual problems such as <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>.</p>
<p>Monotherapies of benazepril and amlodipine have been evaluated for safety in clinical trials in over 6,000 and 11,000 patients, respectively. The observed adverse reactions to the monotherapies in these trials were similar to those seen in trials of Lotrel. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2 Post-marketing Experience</span></h2>
<p class="First">Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>In postmarketing experience with benazepril, there have been rare reports of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. Gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and hepatic enzyme elevations (mostly consistent with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> severe enough to require hospitalization) have been reported in association with use of amlodipine. Other potentially important adverse experiences attributed to other ACE inhibitors and calcium channel blockers include: eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> (ACE inhibitors) and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> (CCBs).  Other infrequently reported events included <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, ventricular extrasystole, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>
<span class="Bold">7</span><span class="Bold">  </span><span class="Bold">DRUG INTERACTIONS</span>
</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="s7p1"></a><a name="section-7.1"></a><p></p>
<h2>
<span class="Bold">7.1 </span><span class="Bold">Drug/Drug interactions</span>
</h2>
<p class="First"><span class="Bold Italics">Diuretics:</span> Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotrel. The possibility of hypotensive effects with Lotrel can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotrel.</p>
<p><span class="Bold Italics">Potassium Supplements and Potassium-Sparing Diuretics:</span> Benazepril can attenuate potassium loss caused by thiazide diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. If concomitant use of such agents is indicated, the patient’s serum potassium should be monitored frequently.</p>
<p><span class="Bold Italics">Lithium:</span> Increased serum lithium levels and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported in patients receiving ACE inhibitors during therapy with lithium. When coadministering Lotrel and lithium, frequent monitoring of serum lithium levels is recommended.</p>
<p><span class="Bold Italics">Gold: </span> Nitritoid reactions (symptoms include <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy.</p>
<p><span class="Bold Italics">Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors):</span> In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including benazepril, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. These effects are usually reversible. Monitor renal function periodically in patients receiving benazepril and NSAID therapy.</p>
<p>The antihypertensive effect of ACE inhibitors, including benazepril, may be attenuated by NSAIDs.</p>
<p><span class="Bold Italics">Simvastatin: </span>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p>
<p><span class="Bold Italics">Other:</span> Benazepril has been used concomitantly with oral anticoagulants, beta-adrenergic-blocking agents, calcium-blocking agents, cimetidine, diuretics, digoxin, and hydralazine without evidence of clinically important adverse interactions.</p>
<p>In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, ACE inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, nonsteroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs.</p>
<p>In vitro data in human plasma indicate that amlodipine has no effect on the protein binding of drugs tested (digoxin, phenytoin, warfarin, and indomethacin). Special studies have indicated that the coadministration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers; that coadministration with cimetidine did not alter the pharmacokinetics of amlodipine; and that coadministration with warfarin did not change the warfarin-induced <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> response time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold">7.2 Clinical Laboratory Test Findings</span></h2>
<p class="First"><span class="Bold Italics">Serum Electrolytes:</span> [see <span class="Italics">Warnings and Precautions</span> (5)].</p>
<p><span class="Bold Italics">Creatinine:</span> Minor reversible increases in serum creatinine were observed in patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> treated with Lotrel. Increases in creatinine are more likely to occur in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or those pretreated with a diuretic and, based on experience with other ACE inhibitors, would be expected to be especially likely in patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">renal artery stenosis</span> [see <span class="Italics">Warnings and Precautions</span> (5)].</p>
<p><span class="Bold Italics">Other</span> (causal relationships unknown): Clinically important changes in standard laboratory tests were rarely associated with Lotrel administration. Elevations of serum bilirubin and uric acid have been reported as have scattered incidents of elevations of liver enzymes.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">8</span><span class="Bold">  </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">8.1 </span><span class="Bold">Pregnancy</span>
</h2>
<p class="First">Pregnancy Category D</p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations.  Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  When pregnancy is detected, discontinue Lotrel as soon as possible.  These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy.  Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.  Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus.</p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus.  Perform serial ultrasound examinations to assess the intra-amniotic environment.  If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue Lotrel, unless it is considered lifesaving for the mother.  Fetal testing may be appropriate, based on the week of pregnancy.  Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.  Closely observe infants with histories of in utero exposure to Lotrel for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> <span class="Italics">[see Use in Specific Populations (8.4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">8.2 </span><span class="Bold">Labor and Delivery</span>
</h2>
<p class="First">The effect of Lotrel on labor and delivery has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8p3"></a><a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">8.3 </span><span class="Bold">Nursing Mothers</span>
</h2>
<p class="First">Minimal amounts of unchanged benazepril and of benazeprilat are excreted into the breast milk of lactating women treated with benazepril, so that a newborn child ingesting nothing but breast milk would receive less than 0.1% of the maternal doses of benazepril and benazeprilat.</p>
<p>It is not known whether amlodipine is excreted in human milk. Nursing or drug should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.4 </span><span class="Bold">Pediatric Use</span>
</h2>
<p class="First"><span class="Underline">Neonates with a history of in utero exposure to Lotrel:</span></p>
<p>If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion.  Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function. Benazepril, which crosses the placenta, can theoretically be removed from the neonatal circulation by these means; there are occasional reports of benefit from these maneuvers, but experience is limited.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.5"></a><p></p>
<h2>
<span class="Bold">8.5 </span><span class="Bold">Geriatric Use</span>
</h2>
<p class="First">Of the total number of patients who received Lotrel in U.S. clinical studies of Lotrel, over 19% were 65 or older while about 2% were 75 or older. Overall differences in effectiveness or safety were not observed between these patients and younger patients. Clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Benazepril and benazeprilat are substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
<p>Amlodipine is extensively metabolized in the liver. In the elderly, clearance of amlodipine is decreased with resulting increases in peak plasma levels, elimination half-life and area-under-the-plasma-concentration curve. Thus a lower starting dose may be required in older patients [<span class="Italics">see</span> <span class="Italics">Dosage and Administration</span> (2)].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">10</span><span class="Bold">  </span><span class="Bold">OVERDOSAGE</span>
</h1>
<p class="First">Only a few cases of human <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with amlodipine have been reported. One patient was asymptomatic after a 250-mg ingestion; another, who combined 70 mg of amlodipine with an unknown large quantity of a benzodiazepine, developed refractory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and died.</p>
<p>Human <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with any combination of amlodipine and benazepril have not been reported. In scattered reports of human <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with benazepril and other ACE inhibitors, there are no reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p><span class="Bold Italics">Treatment:</span> To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison-Control Center. Telephone numbers of certified poison-control centers are listed in the Physicians’ Desk Reference (PDR). In managing <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, consider the possibilities of multiple-drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, drug-drug interactions, and unusual drug kinetics in your patient.</p>
<p>The most likely effect of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Lotrel is vasodilation, with consequent <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Simple repletion of central fluid volume (Trendelenburg positioning, infusion of crystalloids) may be sufficient therapy, but pressor agents (norepinephrine or high-dose dopamine) may be required. With abrupt return of peripheral vascular tone, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of other dihydropyridine calcium channel blockers have sometimes progressed to <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and patients must be monitored for this complication.</p>
<p>Analyses of bodily fluids for concentrations of amlodipine, benazepril, or their metabolites are not widely available. Such analyses are, in any event, not known to be of value in therapy or prognosis.</p>
<p>No data are available to suggest physiologic maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination of amlodipine, benazepril, or their metabolites. Benazeprilat is only slightly dialyzable; attempted clearance of amlodipine by hemodialysis or hemo-perfusion has not been reported, but amlodipine’s high protein binding makes it unlikely that these interventions will be of value.</p>
<p>Angiotensin II could presumably serve as a specific antagonist-antidote to benazepril, but angiotensin II is essentially unavailable outside of scattered research laboratories. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1><span class="Bold">11  DESCRIPTION</span></h1>
<p class="First">Lotrel is a combination of amlodipine besylate and benazepril hydrochloride.</p>
<p>Benazepril hydrochloride is a white to off-white crystalline powder, soluble (&gt;100 mg/mL) in water, in ethanol, and in methanol. Benazepril hydrochloride’s chemical name is 3-[[1-(ethoxycarbonyl)-3-phenyl-(1S)-propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1<span class="Italics">H</span>-1-(3S)-benzazepine-1-acetic acid monohydrochloride; its structural formula is</p>
<p>
		     
	  <img alt="Benazepril hydrochloride structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d&amp;name=lotrel-01.jpg"></p>
<p>Its empirical formula is C<span class="Sub">24</span>H<span class="Sub">28</span>N<span class="Sub">2</span>O<span class="Sub">5</span>•HCl, and its molecular weight is 460.96.</p>
<p>Benazeprilat, the active metabolite of benazepril, is a nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Benazepril is converted to benazeprilat by hepatic cleavage of the ester group.</p>
<p>Amlodipine besylate is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline powder, slightly soluble in water and sparingly soluble in ethanol. Its chemical name is (R,S)3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate benzenesulfonate; its structural formula is</p>
<p>
		     
	   <img alt="Amlodipine besylate structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d&amp;name=lotrel-02.jpg"></p>
<p>Its empirical formula is C<span class="Sub">20</span>H<span class="Sub">25</span>ClN<span class="Sub">2</span>O<span class="Sub">5</span>•C<span class="Sub">6</span>H<span class="Sub">6</span>O<span class="Sub">3</span>S, and its molecular weight is 567.1.</p>
<p>Amlodipine besylate is the besylate salt of amlodipine, a dihydropyridine calcium channel blocker.</p>
<p>Lotrel capsules are formulated in six different strengths for oral administration with a combination of amlodipine besylate equivalent to 2.5 mg, 5 mg or 10 mg of amlodipine, with 10 mg, 20 mg or 40 mg of benazepril hydrochloride providing for the following available combinations: 2.5/10 mg, 5/10 mg, 5/20 mg, 5/40 mg, 10/20 mg and 10/40 mg. </p>
<p>The inactive ingredients of the capsules are calcium phosphate, cellulose compounds, colloidal silicon dioxide, crospovidone, gelatin, hydrogenated castor oil (not present in 5/40 mg or 10/40 mg strengths), iron oxides, lactose, magnesium stearate, polysorbate 80, silicon dioxide, sodium lauryl sulfate, sodium starch (potato) glycolate, starch (corn), talc, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>
<span class="Bold">12</span><span class="Bold">  </span><span class="Bold">CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>
<span class="Bold">12.1 </span><span class="Bold">Mechanism of Action</span>
</h2>
<p class="First"><span class="Bold Italics">Benazepril</span></p>
<p>Benazepril and benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and in animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.</p>
<p>Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. Hypertensive patients treated with benazepril and amlodipine for up to 56 weeks had elevations of serum potassium up to 0.2 mEq/L [see <span class="Italics">Warnings and Precautions</span> (5)].</p>
<p>Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity. In animal studies, benazepril had no inhibitory effect on the vasopressor response to angiotensin II and did not interfere with the hemodynamic effects of the autonomic neurotransmitters acetylcholine, epinephrine, and norepinephrine.</p>
<p>ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of Lotrel remains to be elucidated.</p>
<p>While the mechanism through which benazepril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin aldosterone system, benazepril has an antihypertensive effect even in patients with low-renin <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p><span class="Bold Italics">Amlodipine</span></p>
<p>Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect.</p>
<p>Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and reduction in blood pressure.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>
<span class="Bold">12.2 </span><span class="Bold">Pharmacodynamics</span>
</h2>
<p class="First"><span class="Bold Italics">Benazepril</span></p>
<p>Single and multiple doses of 10 mg or more of benazepril cause inhibition of plasma ACE activity by at least 80%-90% for at least 24 hours after dosing. For up to 4 hours after a 10-mg dose, pressor responses to exogenous angiotensin I were inhibited by 60%-90%.</p>
<p>Administration of benazepril to patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> results in a reduction of both supine and standing blood pressure to about the same extent, with no compensatory <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> is infrequent, although it can occur in patients who are salt and/or volume depleted [see <span class="Italics">Warnings and Precautions</span> (5)].</p>
<p>The antihypertensive effects of benazepril were not appreciably different in patients receiving high- or low-sodium diets.</p>
<p>In normal human volunteers, single doses of benazepril caused an increase in renal blood flow but had no effect on glomerular filtration rate.</p>
<p><span class="Bold Italics">Amlodipine</span></p>
<p>Following administration of therapeutic doses to patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Plasma concentrations correlate with effect in both young and elderly patients.</p>
<p>As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and humans, even when coadministered with beta blockers to humans.</p>
<p>Amlodipine does not change sinoatrial (SA) nodal function or atrioventricular (AV) conduction in intact animals or humans. In clinical studies in which amlodipine was administered in combination with beta blockers to patients with either <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or angina, no adverse effects on electrocardiographic parameters were observed.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>
<span class="Bold">12.3 </span><span class="Bold">Pharmacokinetics</span>
</h2>
<p class="First">The rate and extent of absorption of benazepril and amlodipine from Lotrel are not significantly different, respectively, from the rate and extent of absorption of benazepril and amlodipine from individual tablet formulations. Absorption from the individual tablets is not influenced by the presence of food in the gastrointestinal tract; food effects on absorption from Lotrel have not been studied.</p>
<p>Following oral administration of Lotrel, peak plasma concentrations of benazepril are reached in 0.5-2 hours. Cleavage of the ester group (primarily in the liver) converts benazepril to its active metabolite, benazeprilat, which reaches peak plasma concentrations in 1.5-4 hours. The extent of absorption of benazepril is at least 37%.</p>
<p>Peak plasma concentrations of amlodipine are reached 6-12 hours after administration of Lotrel; the extent of absorption is 64%-90%.</p>
<p>The apparent volumes of distribution of amlodipine and benazeprilat are about 21 L/kg and 0.7 L/kg, respectively. Approximately 93% of circulating amlodipine is bound to plasma proteins, and the bound fraction of benazeprilat is slightly higher. On the basis of in vitro studies, benazeprilat’s degree of protein binding should be unaffected by age, by hepatic dysfunction, or—over the therapeutic concentration range—by concentration.</p>
<p>Benazeprilat has much greater ACE-inhibitory activity than benazepril, and the metabolism of benazepril to benazeprilat is almost complete. Only trace amounts of an administered dose of benazepril can be recovered unchanged in the urine; about 20% of the dose is excreted as benazeprilat, 8% as benazeprilat glucuronide, and 4% as benazepril glucuronide.</p>
<p>Amlodipine is extensively metabolized in the liver, with 10% of the parent compound and 60% of the metabolites excreted in the urine. In patients with hepatic dysfunction, decreased clearance of amlodipine may increase the area-under-the-plasma-concentration curve by 40%-60%, and dosage reduction may be required [see<span class="Italics"> Dosage and Administration (2)</span>]. In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the pharmacokinetics of amlodipine are essentially unaffected.</p>
<p>Benazeprilat’s effective elimination half-life is 10-11 hours, while that of amlodipine is about 2 days, so steady-state levels of the two components are achieved after about a week of once-daily dosing. The clearance of benazeprilat from the plasma is primarily renal, but biliary excretion accounts for 11%-12% of benazepril elimination in normal subjects. In patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance less than 30 mL/min), peak benazeprilat levels and the time to steady state may be increased [see<span class="Italics"> Dosage and Administration (2)</span>]. In patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, on the other hand, the pharmacokinetics of benazeprilat are essentially unaffected.</p>
<p>Although the pharmacokinetics of benazepril and benazeprilat are unaffected by age, clearance of amlodipine is decreased in the elderly, with resulting increases of 35%-70% in peak plasma levels, elimination half-life, and area-under-the-plasma-concentration curve. Dose adjustment may be required.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>
<span class="Bold">13  </span><span class="Bold">NONCLINICAL TOXICOLOGY</span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span>
</h2>
<p class="First">Carcinogenicity and mutagenicity studies have not been conducted with this combination.  However, these studies have been conducted with amlodipine and benazepril alone (see below). No adverse effects on fertility occurred when the benazepril:amlodipine combination was given orally to rats of either sex at doses up to 15:7.5 mg (benazepril:amlodipine)/kg/day, prior to mating and throughout gestation.</p>
<p><span class="Bold Italics">Benazepril</span></p>
<p>No evidence of carcinogenicity was found when benazepril was administered to rats and mice for up to two years at doses of up to 150 mg/kg/day. When compared on the basis of body surface area, this dose is 18 and 9 times (rats and mice, respectively) the maximum recommended human dose (calculations assume a patient weight of 60 kg). No mutagenic activity was detected in the Ames test in bacteria, in an <span class="Italics">in vitro</span> test for forward mutations in cultured mammalian cells, or in a nucleus anomaly test. At doses of 50-500 mg/kg/day (6-60 times the maximum recommended human dose on a body surface area basis), benazepril had no adverse effect on the reproductive performance of male and female rats.</p>
<p><span class="Bold Italics">Amlodipine</span></p>
<p>Rats and mice treated with amlodipine maleate in the diet for up to two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg amlodipine/kg/day, showed no evidence of a carcinogenic effect of the drug. For the mouse, the highest dose was, on a body surface area basis, similar to the maximum recommended human dose [MRHD] of 10 mg amlodipine/day. For the rat, the highest dose was, on a body surface area basis, about two and a half times the MRHD. (Calculations based on a 60 kg patient.)  Mutagenicity studies conducted with amlodipine maleate revealed no drug-related effects at either the gene or chromosome level.   There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses of up to 10 mg amlodipine/kg/day (about 10 times the MRHD of 10 mg/day on a body surface area basis). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>
<span class="Bold">13.3 </span><span class="Bold">Reproductive </span><span class="Bold">Toxicity</span>
</h2>
<p class="First">When rats received benazepril:amlodipine at doses ranging from 5:2.5 to 50:25 mg/kg/day, dystocia was observed at an increasing dose-related incidence at all doses tested. On a body surface area basis, the 2.5 mg/kg/day dose of amlodipine is 3.6 times the amlodipine dose delivered when the maximum recommended dose of Lotrel is given to a 50-kg woman. Similarly, the 5 mg/kg/day dose of benazepril is approximately twice the benazepril dose delivered when the maximum recommended dose of Lotrel is given to a 50-kg woman.  No teratogenic effects were seen when benazepril and amlodipine were administered in combination to pregnant rats or rabbits. Rats received doses of up to 50:25 mg (benazepril:amlodipine)/kg/day (24 times the maximum recommended human dose on a body surface area basis, assuming a 50-kg woman). Rabbits received doses of up to 1.5:0.75 mg/kg/day (equivalent to the maximum recommended dose of Lotrel given to a 50-kg woman).</p>
<p><span class="Bold Italics">Benazepril</span></p>
<p>No teratogenic effects of benazepril were seen in studies of pregnant rats, mice, and rabbits. On a body surface area basis, the maximum doses used in these studies were 60 times (in rats), 9 times (in mice), and about equivalent to (in rabbits) the maximum recommended human dose (assuming a 50-kg woman). </p>
<p><span class="Bold Italics">Amlodipine</span></p>
<p>No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses of up to 10 mg amlodipine/kg/day (respectively, about 10 and 20 times the maximum recommended human dose [MRHD] of 10 mg amlodipine on a body surface area basis) during their respective periods of major organogenesis. (Calculations based on a patient weight of 60 kg.) However, litter size was significantly decreased (by about 50%) and the number of intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> was significantly increased (about 5-fold) for rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose. There are no adequate and well-controlled studies in pregnant women. Amlodipine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>
<span class="Bold">14  </span><span class="Bold">CLINICAL STUDIES</span>
</h1>
<p class="First">Over 950 patients received Lotrel once daily in six double-blind, placebo-controlled studies. The antihypertensive effect of a single dose persisted for 24 hours, with peak reductions achieved 2-8 hours after dosing.</p>
<p>Once-daily doses of benazepril/amlodipine using benazepril doses of 10-20 mg and amlodipine doses of 2.5-10 mg decreased seated pressure (systolic/diastolic) 24 hours after dosing by about 10-25/6-13 mmHg.</p>
<p>In two studies in patients not adequately controlled on either benazepril 40 mg alone (n=329) or amlodipine 10 mg alone (n=812) once daily doses of Lotrel 10/40 mg further decreased seated blood pressure compared to the respective monotherapy alone.</p>
<p>Combination therapy was effective in blacks and nonblacks. Both components contributed to the antihypertensive efficacy in nonblacks, but virtually all of the antihypertensive effect in blacks could be attributed to the amlodipine component. Among nonblack patients in placebo-controlled trials comparing Lotrel to the individual components, the blood pressure lowering effects of the combination were shown to be additive and in some cases synergistic.</p>
<p>During chronic therapy with Lotrel, the maximum reduction in blood pressure with any given dose is generally achieved after 1-2 weeks. The antihypertensive effects of Lotrel have continued during therapy for at least 1 year. Abrupt withdrawal of Lotrel has not been associated with a rapid increase in blood pressure.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>
<span class="Bold">16</span><span class="Bold">  </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<p class="First">Lotrel is available as capsules containing amlodipine besylate equivalent to 2.5 mg, 5 mg or 10 mg of amlodipine, with 10 mg, 20 mg or 40 mg of benazepril hydrochloride providing for the following available combinations: 2.5/10 mg, 5/10 mg, 5/20 mg, 5/40 mg, 10/20 mg and 10/40 mg. All six strengths are packaged in bottles of 100 capsules.</p>
<p>Capsules are imprinted with “Lotrel? and appropriate code.</p>
<a name="ibaeaecb4-a9ff-4cc6-8be6-107ace9df01d"></a><table width="50%"><tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Dose</span><br>
</td>
<td>
<span class="Bold">Capsule Color/Code</span><br>
</td>
<td>
<span class="Bold">Bottles of</span><br>
</td>
<td>
<span class="Bold">NDC Code</span><br>
</td>
</tr>
<tr>
<td>2.5/10 mg<br>
</td>
<td>white with 2 gold bands/2255<br>
</td>
<td>10<br>
</td>
<td>54868-4066-1<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>30<br>
</td>
<td>54868-4066-0<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>5/10 mg<br>
</td>
<td>light brown with 2 white bands/2260<br>
</td>
<td>10<br>
</td>
<td>54868-4073-1<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>30<br>
</td>
<td>54868-4073-0<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>60<br>
</td>
<td>54868-4073-2<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>100<br>
</td>
<td>54868-4073-3<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>5/20 mg<br>
</td>
<td>pink with 2 white bands/2265<br>
</td>
<td>10<br>
</td>
<td>54868-4074-2<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>30<br>
</td>
<td>54868-4074-0<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>60<br>
</td>
<td>54868-4074-4<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>90<br>
</td>
<td>54868-4074-1<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>100<br>
</td>
<td>54868-4074-3<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>5/40 mg<br>
</td>
<td>light blue with 2 white bankds/0384<br>
</td>
<td>10<br>
</td>
<td>54868-5783-0<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>30<br>
</td>
<td>54868-5783-1<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>10/20 mg<br>
</td>
<td>purple (amethyst) with 2 white bands/0364<br>
</td>
<td>10<br>
</td>
<td>54868-4870-1<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>30<br>
</td>
<td>54868-4870-0<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>90<br>
</td>
<td>54868-4870-2<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>10/40 mg<br>
</td>
<td>dark blue with 2 white bands/0379<br>
</td>
<td>10<br>
</td>
<td>54868-5690-0<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>30<br>
</td>
<td>54868-5690-1<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>90<br>
</td>
<td>54868-5690-3<br>
</td>
</tr>
<tr class="Last">
<td><br></td>
<td><br></td>
<td>100<br>
</td>
<td>54868-5690-2<br>
</td>
</tr>
</tbody></table>
<br><p>Storage: Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).  [See USP controlled room temperature.]  Protect from moisture. Dispense in tight container (USP).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>
<span class="Bold">17</span><span class="Bold">  </span><span class="Bold">PATIENT COUNSELING INFORMATION</span>
</h1>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Information for Patients</span></p>
<p>Female patients of childbearing age should be told about the consequences of exposure to Lotrel during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling</span></p>
<p><span class="Bold">LOTREL</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">‚ (low-TREL)</span></p>
<p><span class="Bold">amlodipine besylate/benazepril hydrochloride capsules</span></p>
<p>Read this Patient Information leaflet before you start taking LOTREL and each time you get a refill. There may be new information. This leaflet does not replace talking with your doctor. If you have any questions, ask your doctor or pharmacist.</p>
<a name="i6619635f-ce9e-44be-8b26-5f7435d991a7"></a><table>
<col width="734">
<tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule Toprule">
<span class="Bold">What is the most important information I should know about LOTREL?</span><ul class="Disc">
<li>LOTREL can cause harm or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to an unborn baby.</li>
<li>Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant.</li>
<li>If you get pregnant while taking LOTREL, tell your doctor right away.</li>
</ul>
</td></tr></tbody>
</table>
<p><span class="Bold">What is LOTREL?</span></p>
<p>LOTREL contains two prescription medicines that work together to lower blood pressure: amlodipine besylate (the active ingredient found in Norvasc<span class="Sup">®</span>), a calcium channel blocker, and benazepril hydrochloride (Lotensin®), an ACE inhibitor. Your doctor will prescribe LOTREL only after other medicines haven’t worked.</p>
<p><span class="Bold">High Blood Pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></span>). Blood pressure is the force of blood in your blood vessels. You have high blood pressure when the force is too much. LOTREL can help your blood vessels relax so your blood pressure is lower.</p>
<p>LOTREL has not been studied in children.</p>
<p><span class="Bold">Who should not take LOTREL?</span></p>
<p><span class="Bold">Don’t take LOTREL if you are allergic to any of the ingredients.</span> There is a complete list at the end of this leaflet.</p>
<p><span class="Bold">What should I tell my Doctor before taking LOTREL?</span></p>
<p>Tell your doctor about all your medical conditions, including if:</p>
<ul class="Disc">
<li>
<span class="Bold">you are pregnant or plan to become pregnant.</span> See “What is the most important information I should know about LOTREL??<br>
</li>
<li>
<span class="Bold">you are breastfeeding.</span> LOTREL may pass into your milk. Don’t breastfeed while you are taking LOTREL.<br>
</li>
<li>you have a heart condition<br>
</li>
<li>you have liver problems<br>
</li>
<li>you have kidney problems<br>
</li>
<li>you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (high blood sugar)<br>
</li>
<li>you have <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> (SLE), <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">scleroderma</span> or a collagen vascular disease. Ask your doctor if you are not sure.</li>
</ul>
<p>Keep a list of your medicines with you, including vitamins and natural or herbal remedies, to show your doctor or pharmacist. Some of your other medicines and LOTREL could affect each other, causing serious side effects. Tell your doctor about all your medicines, especially:</p>
<ul class="Disc">
<li>medicines for high blood pressure or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span><br>
</li>
<li>water pills, extra potassium or a salt substitute<br>
</li>
<li>Lithium (Eskalith<span class="Sup">®</span>, Lithobid<span class="Sup">®</span>)</li>
</ul>
<p><span class="Bold">How do I take LOTREL?</span></p>
<ul class="Disc">
<li>Take LOTREL exactly as your doctor tells you.<br>
</li>
<li>Take LOTREL at the same time each day, with or without food.<br>
</li>
<li>If you miss a dose, take it as soon as you remember. If it is more than 12 hours, just take your next dose at the regular time.<br>
</li>
<li>Your doctor may test for kidney problems or check your <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> level.<br>
</li>
<li>If you take too much LOTREL, call your doctor or Poison Control Center, or go to the emergency room.<br>
</li>
<li>Tell all your doctors or dentist you are taking LOTREL if you:<br>-  are going to have surgery<br>-  are getting <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> shots for bee <span class="product-label-link" type="condition" conceptid="4083844" conceptname="Bee sting">stings</span><br>-  go for kidney dialysis</li>
</ul>
<p><span class="Bold">What are the possible side effects of LOTREL?</span></p>
<p>LOTREL can cause serious side effects including:</p>
<ul class="Disc"><li>
<span class="Bold">serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> that can be life threatening.</span><br>Stop LOTREL and get emergency help right away if you get:<br>
		     
	-
		     
	<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyelids, lips, tongue or throat<br>
		     
	-
		     
	have trouble swallowing<br>
		     
	-
		     
	<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>) or other breathing problems<br>These <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> are rare but happen more times in people who are African-American.</li></ul>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>). <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> is most likely to happen if you also take water pills, are on a low salt diet, get dialysis treatments, have heart problems or get sick with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Lie down if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy.<br>
</li>
<li>
<span class="Bold">liver problems.</span> Call your doctor if:<br>
</li>
<li>you have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span><br>
</li>
<li>you feel more tired or weaker than usual<br>
</li>
<li>you have <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span><br>
</li>
<li>your skin or eyes look yellow<br>
</li>
<li>you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your upper right stomach<br>
</li>
<li>you have flu-like symptoms<br>
</li>
<li>
<span class="Bold">low white blood cells.</span> Low white blood cells happen more in people who have kidney problems and collagen vascular diseases. Low white blood cells can give you a higher chance for getting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Call your doctor if you get a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that do not go away.<br>
</li>
<li>
<span class="Bold">kidney problems.</span> Kidney problems may get worse in people that already have kidney disease. Some people will have changes on blood tests for kidney function and need a lower dose of LOTREL. Call your doctor if you get <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your feet, ankles, or hands or unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.<br>
</li>
<li>
<span class="Bold">more <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span></span> in people that already have severe heart problems. Get emergency help if you get worse <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> that does not go away.</li>
</ul>
<p>The more common side effects of LOTREL are:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>
		     
	<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of the feet, ankles, and hands</li>
</ul>
<p>These are not all the side effects of LOTREL. For a complete list, ask your doctor or pharmacist.</p>
<p><span class="Bold">How do I store LOTREL?</span></p>
<ul class="Disc">
<li>Store LOTREL at room temperature (59-86°F).<br>
</li>
<li>Keep LOTREL in a closed container in a dry place.<br>
</li>
<li>Keep LOTREL and all medicines out of the reach of children.</li>
</ul>
<p><span class="Bold">General Information about LOTREL</span></p>
<p>Doctors can also use medicine for a condition that is not in the patient information leaflet. Take LOTREL the way your doctor tells you. Do not share it with other people. It may harm them.</p>
<p>For more information, ask your doctor or pharmacist, visit www.LOTREL.com on the Internet, or call 1-888-669-6682.</p>
<p><span class="Bold">What are the ingredients in LOTREL?</span></p>
<p>Active ingredients: amlodipine besylate (the active ingredient found in Norvasc®), benazepril hydrochloride (Lotensin®)</p>
<p>Inactive ingredients: calcium phosphate, cellulose compounds, colloidal silicon dioxide, crospovidone, gelatin, hydrogenated castor oil (not present in 5/40 mg and 10/40 mg strengths), iron oxides, lactose, magnesium stearate, polysorbate 80, silicon dioxide, sodium lauryl sulfate, sodium starch (potato) glycolate, starch (corn), talc, and titanium dioxide.</p>
<p>Norvasc® is a registered trademark of Pfizer, Inc.  Lotensin® is a registered trademark of Novartis Corp.  Eskalith® and Lithobid® are registered trademarks of Noven Therapeutics, LLC.  </p>
<p>Distributed by:<br>Novartis Pharmaceuticals Corporation<br>East Hanover, New Jersey 07936</p>
<p>© Novartis</p>
<p>T2012-43/T2012-44<br>January 2012/January 2012</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma        74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – 2.5 / 10 mg</span></p>
<p>Rx Only
		     
	
		      <br></p>
<p>Lotrel® </p>
<p>amlodipine besylate</p>
<p>(equivalient to amlodipine 2.5 mg)</p>
<p>benazepril HCL 10 mg</p>
<div class="Figure"><img alt="image of 2.5/10 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d&amp;name=4066.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – 5/ 10 mg</span></p>
<p>Rx Only
		     
	
		      <br></p>
<p>Lotrel® </p>
<p>amlodipine besylate</p>
<p>(equivalient to amlodipine 5 mg)</p>
<p>benazepril HCL 10 mg</p>
<div class="Figure"><img alt="image of 5/10 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d&amp;name=4073.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – 5/ 20 mg</span></p>
<p>Rx Only
		     
	
		      <br></p>
<p>Lotrel® </p>
<p>amlodipine besylate</p>
<p>(equivalient to amlodipine 5 mg)</p>
<p>benazepril HCL 20 mg</p>
<div class="Figure"><img alt="image of 5/20 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d&amp;name=4074.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – 5/ 40 mg</span></p>
<p>Rx Only
		     
	
		      <br></p>
<p>Lotrel® </p>
<p>amlodipine besylate</p>
<p>(equivalient to amlodipine 5 mg)</p>
<p>benazepril HCL 40 mg</p>
<div class="Figure"><img alt="image of 5/40 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d&amp;name=5783.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – 10 / 20 mg</span></p>
<p>Rx Only
		     
	
		      <br></p>
<p>Lotrel® </p>
<p>amlodipine besylate</p>
<p>(equivalient to amlodipine10 mg)</p>
<p>benazepril HCL 20 mg</p>
<div class="Figure"><img alt="image of 10/20 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d&amp;name=4870.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – 10 / 40 mg</span></p>
<p>Rx Only
		     
	
		      <br></p>
<p>Lotrel® </p>
<p>amlodipine besylate</p>
<p>(equivalient to amlodipine10 mg)</p>
<p>benazepril HCL 40 mg</p>
<div class="Figure"><img alt="image of 10/40 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d&amp;name=5690.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOTREL 		
					</strong><br><span class="contentTableReg">amlodipine besylate and benazepril hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4066(NDC:0078-0404)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">2.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BENAZEPRIL HYDROCHLORIDE</strong> (BENAZEPRILAT) </td>
<td class="formItem">BENAZEPRIL HYDROCHLORIDE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROGENATED CASTOR OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white with 2 gold bands) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Lotrel;2255</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4066-0</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4066-1</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020364</td>
<td class="formItem">02/02/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOTREL 		
					</strong><br><span class="contentTableReg">amlodipine besylate and benazepril hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4073(NDC:0078-0405)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BENAZEPRIL HYDROCHLORIDE</strong> (BENAZEPRILAT) </td>
<td class="formItem">BENAZEPRIL HYDROCHLORIDE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROGENATED CASTOR OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (light brown with 2 white bands) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Lotrel;2260</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4073-0</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4073-1</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-4073-2</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-4073-3</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020364</td>
<td class="formItem">07/01/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOTREL 		
					</strong><br><span class="contentTableReg">amlodipine besylate and benazepril hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4074(NDC:0078-0406)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BENAZEPRIL HYDROCHLORIDE</strong> (BENAZEPRILAT) </td>
<td class="formItem">BENAZEPRIL HYDROCHLORIDE</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROGENATED CASTOR OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (pink with 2 white bands) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Lotrel;2265</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4074-0</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4074-1</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-4074-2</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-4074-3</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-4074-4</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020364</td>
<td class="formItem">11/28/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOTREL 		
					</strong><br><span class="contentTableReg">amlodipine besylate and benazepril hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5783(NDC:0078-0384)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BENAZEPRIL HYDROCHLORIDE</strong> (BENAZEPRILAT) </td>
<td class="formItem">BENAZEPRIL HYDROCHLORIDE</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (light blue with 2 white bands) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Lotrel;0384</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5783-0</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5783-1</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020364</td>
<td class="formItem">06/20/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOTREL 		
					</strong><br><span class="contentTableReg">amlodipine besylate and benazepril hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4870(NDC:0078-0364)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BENAZEPRIL HYDROCHLORIDE</strong> (BENAZEPRILAT) </td>
<td class="formItem">BENAZEPRIL HYDROCHLORIDE</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROGENATED CASTOR OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE (purple (amethyst) with 2 white bands) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Lotrel;0364</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4870-0</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4870-1</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-4870-2</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020364</td>
<td class="formItem">07/30/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOTREL 		
					</strong><br><span class="contentTableReg">amlodipine besylate and benazepril hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5690(NDC:0078-0379)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BENAZEPRIL HYDROCHLORIDE</strong> (BENAZEPRILAT) </td>
<td class="formItem">BENAZEPRIL HYDROCHLORIDE</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (dark blue with 2 white bands) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Lotrel;0379</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5690-0</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5690-1</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5690-2</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-5690-3</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020364</td>
<td class="formItem">10/10/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8a1277c4-9a11-4cc9-8a6b-aea181d8c75c</div>
<div>Set id: 4653cabc-f249-4b4e-95b6-5fb4ddc0ad5d</div>
<div>Version: 3</div>
<div>Effective Time: 20120302</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
